Biogen Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.74%.
Did BIIB Beat Earnings? Q1 2025 Results
Biogen posted a mixed but ultimately encouraging first quarter for 2025, with a top-line beat obscuring a narrow earnings miss as the company's strategic pivot toward rare disease continued to reshape its revenue profile. Total revenue climbed 6.1% year-over-year to $2.43 billion, well ahead of the $2.23 billion consensus, while non-GAAP diluted EPS of $3.02 fell just short of the $3.04 estimate, weighed down by a roughly $0.95 per-share headwind from a $165 million upfront payment to Stoke Therapeutics for a collaboration on zorevunersen. Rare disease revenue surged 33% to $563 million, underscoring how meaningfully the business has diversified, with nearly 45% of product revenue now generated outside the legacy multiple sclerosis franchise, which itself declined 11% to $953 million. LEQEMBI global in-market sales reached approximately $96 million, aided by a European approval during the quarter. Looking ahead, Biogen trimmed its full-year non-GAAP EPS guidance to $14.50 to $15.50, reflecting the Stoke payment, though management noted the company's substantial U.S. manufacturing presence offers meaningful insulation from tariff headwinds.
- Portfolio transformation with ~45% of total product revenue from medicines outside MS business
- Rare disease revenue growth of 33% YoY driven by SPINRAZA shipment timing and SKYCLARYS demand growth
- Contract manufacturing, royalty and other revenue growth of 61% YoY
- Fit for Growth initiative generating R&D and SG&A savings
- LEQEMBI continued sequential growth with global in-market sales of ~$96 million
- Product mix shift partially offset by launch product revenue growth
“Biogen delivered strong first-quarter results, supporting our strategy for long-term growth. We are encouraged by the transformation in our commercial product portfolio, with approximately 45% of total product revenue in the first quarter derived from important medicines outside of our MS business.”
Biogen CEO, on the earnings call
Forward Guidance & Outlook
Biogen updated full year 2025 Non-GAAP diluted EPS guidance to $14.50–$15.50, down from prior guidance of $15.25–$16.25, reflecting the ~$0.95 impact from the $165 million Stoke upfront payment partially offset by a $0.20 benefit from more favorable foreign exchange. Total revenue for 2025 is expected to decline by a mid-single digit percentage at constant currency versus 2024, as further MS revenue declines are expected to be partially offset by growth in launch product revenue. Combined Non-GAAP R&D and SG&A expense is expected to total approximately $3.9 billion. The Fit for Growth program is expected to generate approximately $1 billion of gross savings and $800 million net of reinvestment by end of 2025. The company's 2025 outlook is not expected to be materially impacted by potential tariffs given significant U.S. manufacturing presence and current global inventory positions.
BIIB YoY Financials
BIIB Revenue by Segment
BIIB Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.